CIRS is governed by its own dedicated advisory boards made up of external international experts from academia, industry, regulatory agencies and HTA bodies.

The Scientific Advisory Council (SAC) and HTA Steering Committee advise CIRS on workshops, special projects, publications as well as the research programme, to ensure neutrality and that the areas are unbiased and the programme meets the needs to all stakeholders. The selection of Committee Members and Chairs is set out in the Terms of Reference of each committee.

Scientific Advisory Council (SAC)
Chair: Adjunct Prof John Skerritt Deputy Secretary for Health Products Regulation, Department of Health, Australia
Vice-Chair: Prof Hans-Georg Eichler Consulting Physician of the Association of Austrian Social Insurance Institutions
Dr Fabio Bisordi Global Head International Regulatory Policy, F.Hoffman-LaRoche Ltd
Dr Claus Bolte Head of Sector Marketing Authorisation, Swissmedic
Dr Harald Enzmann Chair, European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
Dr Carlos Garner Vice President, Global Regulatory Affairs, Eli Lilly and Co.
Adrian Griffin Vice President for HTA Policy, Johnson & Johnson
Dr Ian Hudson Senior Advisor, Integrated Development, Global Health, Bill and Melinda Gates Foundation
Dr David Jefferys SVP, Head of Global Regulatory, Eisai Europe Ltd
Prof John Lim Executive Director of Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School and Chairman, Consortium for Clinical Research & Innovation Singapore
Dr Sabine Luik Chief Medical Officer and Senior Vice President, Global Medical, Regulatory & Quality, GlaxoSmithKline
Dr Jacques Mascaro Senior Vice President, Oncology Regulatory Science, Strategy and Excellence, AstraZeneca
Dr Theresa Mullin Director, Office of Strategic Programs, US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER)
Dr Brian O’Rourke Former CEO and President, Canadian Agency for Drugs and Technologies in Health (CADTH), Canada
Dr Junko Sato Office Director, Office of International Program, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Dr Xie Songmei Deputy Director of Clinical Department Center for Drug Evaluation, National Medical Products  Administration (NMPA), China
Jerry Stewart Vice President, Head of Global Regulatory Policy & Intelligence, Pfizer
Dr John Patrick Stewart Director General, Therapeutic Products Directorate, Health Canada
Dr Stefan Thirstrup Chief Medical Officer, EMA
Natalie Tolli Vice President, Regulatory Affairs (Regulatory International, Regulatory Policy & Intelligence), Abbvie
Prof Stuart Walker Founder, CIRS
Dr Max Wegner Senior Vice President, Head of Regulatory Affairs, Bayer
Specialist Advisors
Dr Thomas Lönngren Former Executive Director, EMA
Dr Murray Lumpkin Deputy Director, Integrated Development, and Lead for Global Regulatory Systems Initiatives, Bill and Melinda Gates Foundation
Prof Mamoru Narukawa Professor, Pharmaceutical Medicine, Kitasato University Graduate School of Pharmaceutical Sciences, Japan
Dr Tomas Salmonson  Former Chair, CHMP/EMA
Dr Joseph Scheeren Former President and CEO, Critical Path Institute
HTA Steering Committee
Chair: Dr Brian O’Rourke Former CEO and President, CADTH, Canada
Vice-Chair: Prof Adrian Towse Director Emeritus and Senior Research Fellow, Office of Health Economics (OHE)
Dr Indranil Bagchi Senior Vice President and Worldwide Head of Value and Access, Novartis
Prof Finn Børlum Kristensen Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director, Faculty of Health Sciences, University of Southern Denmark
Dr Nick Crabb Programme Director, Scientific Affairs, National Institute for Health and Care Excellence (NICE)
Prof Hans-Georg Eichler Consulting Physician of the Association of Austrian Social Insurance Institutions
Dr Melinda Goodall Director, Health Technology Assessment Policy Research, Policy Evidence Research, CORE, MSD
Dr Wim Goettsch Associate Professor HTA, Utrecht University and Special Advisor HTA, ZIN, The Netherlands
Adrian Griffin Vice President for HTA Policy, Johnson & Johnson
Dr Michael Happich Director, BioMed HTA, Eli Lilly and Co
Dr Adam Heathfield Senior Director, Patient and Health Impact Innovation Centre, Pfizer
Niklas Hedberg Chief Pharmacist, TLV, Sweden
Suzanne McGurn CEO and President, CADTH, Canada
Andrew Mitchell Former Strategic Advisor, Department of Health, Australia
Dr Detlev Parow Former Head, Department of Medicines, Medical Remedies and Selective Contracts, DAK – Gesundheit, Germany
Dr Vanessa Elisabeth Schaub Global Access Chapter Lead for Evidence, Roche
Dr Anja Schiel Special Adviser, Lead Methodologist in Regulatory and Pharmacoeconomic Statistics, Norwegian Medicines Agency; Vice Chair, Committee for Scientific Consistency and Quality, Joint Scientific Consultations, EUnetHTA21
Dr Sean Tunis Principal, Rubix Health